Recent Updates
Recently added Catalysts
ALT

Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

Tuesday, March 8, 2022 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
Price reaction · baseline $7.09 (2022-03-07 close) · hit after-hours · clean, no other ALT news in the window
day 0 close · peak
+1.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight

Full Press Release Details

Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022.
ShareAdd on Google
Tags: ALT Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Mar 8, 2022

Biotech snapshot

Cash runway
$519M liquidity · $8M/mo burn
~64 mo
Minimal dilution risk
Lead asset
ALT-801Phase 2
Obesity/Overweight →

Catalyst track record

+22%
best trade around ALT's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for ALT.

See every catalyst's timing & PoA →